Viral Hepatitis
Copyright ©The Author(s) 2002. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Dec 15, 2002; 8(6): 1077-1080
Published online Dec 15, 2002. doi: 10.3748/wjg.v8.i6.1077
Detection of soluble TRAIL in HBV infected patients and its clinical implications
Li-Hui Han, Wen-Sheng Sun, Chun-Hong Ma, Li-Ning Zhang, Su-Xia Liu, Qiu Zhang, Li-Fen Gao, You-Hai Chen
Li-Hui Han, Wen-Sheng Sun, Chun-Hong Ma, Li-Ning Zhang, Su-Xia Liu, Qiu Zhang, Li-Fen Gao, Institute of Immunology, Medical College of Shandong University, Jinan 250012, Shandong Province, China
You-Hai Chen, Institute for Human Gene Therapy, University of Pennsylvania, Philadelphia, PA19104, USA
Author contributions: All authors contributed equally to the work.
Supported by the National Natural Science Foundation Community, No.30128023
Correspondence to: Prof Wen-Sheng Sun, Institute of Immunology, Medical College of Shandong University, Jinan 250012, Shandong Province, China. wsw@sdu.edu.cn
Telephone: +86-531-8382038 Fax: +86-0531-8382588
Received: April 18, 2002
Revised: June 4, 2002
Accepted: June 12, 2002
Published online: December 15, 2002
Abstract

AIM: To detect the expression of soluble TRAIL (TNF-related apoptosis inducing ligand, TRAIL) in the peripheral blood of HBV infected patients and try to elucidate whether the expression level of sTRAIL have any correlativity with the clinical staging, the expression level of HBV markers and the degree of liver damage.

METHODS: 52 cases of HBV infected patients were investigated, including 8 HBV carriers, 30 chronic hepatitis B, 11 cirrhotics and 3 HBV infection related hepatocellular carcinoma. Expression of soluble TRAIL and markers of the hepatitis B were mearsured by enzyme-linked immunosorbent assay.

RESULTS: The expression level of sTRAIL in the peripheral blood of the HBV infected patients was significantly higher than that of healthy controls (1378.35 ± 540.23 pg/mL vs 613.75 ± 175.80 pg/mL, P < 0.001). In the group of chronic hepatitis, the expression level of sTRAIL was coincident with the status of the disease and was significantly correlated with the level of ALT. In the group of cirrhosis and liver cancer, its expression level was significantly higher than that of the healthy persons and HBV carriers, but lower than that of the hepatitis B patients; meanwhile, the expression of sTRAIL did not have any correlativity with the functional indexes of the liver.

CONCLUSION: The soluble TRAIL in the HBV infected people may participate in the liver damage. Our results indicated that the expression level of soluble TRAIL may reflect the ravage of liver caused by host immune reaction to a certain degree.

Keywords: $[Keywords]